Opinion of the Transparency Council – active substances amiloridum + hydrochlorothiazidum
At its meeting on 18 July 2022 the Transparency Council adopted Opinion No. 114/2022 on the active substance amiloridum + hydrochlorothiazidum for the off-label indication: renal uremia.
Publication in Public Information Bulletin (BIP)